MA49781A - Expression directe d'anticorps - Google Patents

Expression directe d'anticorps

Info

Publication number
MA49781A
MA49781A MA049781A MA49781A MA49781A MA 49781 A MA49781 A MA 49781A MA 049781 A MA049781 A MA 049781A MA 49781 A MA49781 A MA 49781A MA 49781 A MA49781 A MA 49781A
Authority
MA
Morocco
Prior art keywords
antibodies
direct expression
expression
direct
Prior art date
Application number
MA049781A
Other languages
English (en)
Inventor
Galit Alter
Andrew Geall
Todd Suscovich
Original Assignee
Novartis Ag
Massachusetts Gen Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Massachusetts Gen Hospital filed Critical Novartis Ag
Publication of MA49781A publication Critical patent/MA49781A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32041—Use of virus, viral particle or viral elements as a vector
    • C12N2770/32043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
MA049781A 2014-10-29 2015-10-28 Expression directe d'anticorps MA49781A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14190943 2014-10-29

Publications (1)

Publication Number Publication Date
MA49781A true MA49781A (fr) 2021-06-02

Family

ID=51844553

Family Applications (2)

Application Number Title Priority Date Filing Date
MA040871A MA40871A (fr) 2014-10-29 2015-10-27 Expression directe d'anticorps
MA049781A MA49781A (fr) 2014-10-29 2015-10-28 Expression directe d'anticorps

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA040871A MA40871A (fr) 2014-10-29 2015-10-27 Expression directe d'anticorps

Country Status (4)

Country Link
US (1) US20170313765A1 (fr)
EP (2) EP3212224A1 (fr)
MA (2) MA40871A (fr)
WO (1) WO2016066708A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
EP3497127A1 (fr) * 2016-08-05 2019-06-19 Silarus Therapeutics, Inc. Compositions d'anticorps spécifiques d'erfe et procédés d'utilisation
JP7009448B2 (ja) 2016-08-12 2022-02-10 ヤンセン バイオテツク，インコーポレーテツド 強化されたアゴニスト活性を有する、Ｆｃが遺伝子操作を受けた抗ＴＮＦＲスーパーファミリーメンバー抗体及びその使用方法
WO2018232355A1 (fr) * 2017-06-15 2018-12-20 Modernatx, Inc. Anticorps d'arn
MX2020009326A (es) * 2018-03-08 2020-10-08 Phanes Therapeutics Inc Anticuerpos anti-claudina 18.2 y usos de los mismos.
WO2020092387A1 (fr) * 2018-10-30 2020-05-07 Nantbio, Inc. Système d'arn à auto-réplication
US20220002387A1 (en) * 2018-11-06 2022-01-06 University Of Miami Compositions and Production of Recombinant AAV Viral Vectors Capable of Glycoengineering In Vivo

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4186745A (en) 1976-07-30 1980-02-05 Kauzlarich James J Porous catheters
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US6048729A (en) 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5674192A (en) 1990-12-28 1997-10-07 Boston Scientific Corporation Drug delivery
US6054288A (en) 1991-11-05 2000-04-25 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
US5733761A (en) 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5397307A (en) 1993-12-07 1995-03-14 Schneider (Usa) Inc. Drug delivery PTCA catheter and method for drug delivery
JP3403233B2 (ja) 1994-01-20 2003-05-06 テルモ株式会社 バルーンカテーテル
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
AU9676198A (en) 1997-10-01 1999-04-23 C.R. Bard Inc. Drug delivery and gene therapy delivery system
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
US20110300205A1 (en) 2009-07-06 2011-12-08 Novartis Ag Self replicating rna molecules and uses thereof
CA2840913C (fr) * 2011-07-06 2020-01-21 Novartis Ag Emulsions aqueuses contenant des acides nucleiques
WO2013013013A2 (fr) 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions et procédés de production de glycoprotéines modifiées
LT2970456T (lt) * 2013-03-14 2021-08-10 Translate Bio, Inc. Būdai ir kompozicijos, skirti mrnr koduojamų antikūnų pristatymui

Also Published As

Publication number Publication date
EP3663315A1 (fr) 2020-06-10
US20170313765A1 (en) 2017-11-02
WO2016066708A1 (fr) 2016-05-06
MA40871A (fr) 2017-09-05
EP3212224A1 (fr) 2017-09-06

Similar Documents

Publication Publication Date Title
MA42924A (fr) Variants optimisés d'anticorps anti-vegf
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
KR102355950B9 (ko) Tigit에 대한 항체
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
MA46057A (fr) Anticorps anti-ctla4
MA49726A (fr) Formulation d'anticorps anti-cgrp
MA47472A (fr) Anticorps
MA53297A (fr) Anticorps anti-icos
CL2016001879A1 (es) Anticuerpos humanos a pd-l1
MA44381A (fr) Format d'anticorps hétérodimères multispécifiques
MA51552A (fr) Anticorps anti-ox40 et procédés d'utilisation
MA50352A (fr) Anticorps multispécifiques
MA46180A (fr) Analogues de l'amyline
MA49781A (fr) Expression directe d'anticorps
MA42843A (fr) Anticorps anti-cd115
MA51554A (fr) Anticorps il-6 améliorés
FR3019522B1 (fr) Ensemble sustentateur amovible d'un giravion et giravion
MA44236A (fr) Anticorps anti-tgfbêta 2
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
KR20180085008A (ko) 항-pcsk9 항체 및 그의 용도
MA42690A (fr) Micropropagation d'un dattier abada
MA40512A (fr) Anticorps de l'angiopoïétine-like 4 et procédés d'utilisation correspondants
MA50654A (fr) Anticorps anti-pacap
MA49257A (fr) Anticorps anti-trkb
MA43869A (fr) Anticorps anti-myl9